UBS Initiates Coverage on Amneal Pharmaceuticals with a Buy Rating
On April 17, UBS initiated coverage of Amneal Pharmaceuticals (NASDAQ:AMRX) with a 'Buy' rating and set a $19 price target. The firm cited the recent share selloff as an attractive entry point due to the company's strong growth profile in specialty products like Parkinson’s treatments.
Topics: acquisition investment_advice pharmaceuticals stock_rating